IMPEDE-VTE

IMPEDE‑VTE estimates the risk of venous thromboembolism in multiple myeloma patients initiating therapy.

Immunomodulatory drug use
No0Yes+4
BMI ≥ 25 kg/m2
No0Yes+1
Pelvic, hip or femur fracture
No0Yes+4
Erythropoiesis-stimulating agent
No0Yes+1
Doxorubicin use
No0Yes+3
Dexamethasone use
No0Low dose+2High dose+4
Ethnicity/race is Asian/Pacific Islander
Yes-3No0
History VTE before MM
No0Yes+5
Tunneled line/central venous catheter
No0Yes+2
Existing thromboprophylaxis: therapeutic LMWH or warfarin use
Yes-4No0
Existing thromboprophylaxis: prophylactic LMWH or aspirin use
Yes-3No0

使用適応

Identifies newly diagnosed multiple myeloma patients starting IMiD‑based therapy who need VTE risk stratification. Assists in selecting primary thromboprophylaxis by categorizing patients into low, intermediate, or high risk based on validated predictors. External validation shows moderate discrimination (c‑statistic ~0.64) and superior performance to IMWG/NCCN criteria 1 [Level II evidence].

洞察と注意事項

Stratify MM patients on IMiD‑based therapy into low, intermediate, and high VTE risk, but apply cautiously because external validation shows borderline discrimination (c‑statistic ~0.64) and need for prospective validation 1 [Level II evidence]; 2 [Level II evidence]. Insights: captures MM‑specific treatment triggers; simple to score. Cautions: risk inflation with multiple time‑varying factors, limited generalizability, and not yet guideline‑endorsed as definitive.